Breast Cancer Clinical Trial
Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer
Summary
This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the treatment of breast cancer.
Full Description
One of the side effects observed in breast cancer patients receiving anthracycline-based treatment is heart complications in which the heart muscle is weakened and no longer able to pump sufficient amounts of blood throughout the body. This complication can lead to the following symptoms: shortness of breath on exertion, swollen ankles and feet, lack of energy and a reduced capacity to carry out day-to-day activities.
This research study is focused on identifying the early signs of such heart complications using CMR, which may allow preventative treatment options to be made available in future.
Eligibility Criteria
Inclusion Criteria:
Age > 18 years
Have histologic diagnosis of breast carcinoma
Scheduled to receive standard clinical therapy designed by their treating oncologist
Patients should receive anthracycline as part of the recommended treatment
Able to give informed consent.
Exclusion Criteria:
Contraindication to contrast CMR including eGFR <30 mls/min/1.73m2
Uncontrolled serious concurrent illness
Pregnancy or breast feeding
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Boston Massachusetts, 02115, United States More Info
Principal Investigator
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.